Triple-therapy breakthrough halts pancreatic tumors in mice
Spanish CNIO researchers report that a triple combination therapy—an experimental KRAS inhibitor, an existing lung-cancer drug, and a protein degrader—caused long-lasting regression and prevented recurrence of pancreatic ductal adenocarcinoma in three mouse models, a potential path toward new clinical trials, though optimization for patients and trials is not yet planned.